U.S. Medical Equipment Stock News

The latest merger speculation swirling around AstraZeneca and Bristol Myers Squibb has pushed large cap pharma stocks back into the spotlight. Sharp price moves, including AstraZeneca’s intraday fall of up to 7% and a 6% premarket jump for Bristol Myers, show how quickly sentiment can shift when potential mega deals hit the headlines. For investors, this kind of disruption can surface both opportunities and risks. This article looks at 3 stocks from a Healthcare screener that are exposed to...

Antero Midstream Corporation recently reported its second-quarter 2026 results, with revenue rising to US$327.24 million while net income eased to US$113.52 million, alongside record adjusted EBITDA and gathering volumes above 4.1 Bcf per day. The company also received over US$370 million in damages and interest, lowering pro forma leverage to 2.8 times and supporting major pipeline expansion plans, including the East Side Express project. We’ll now examine how the damages-driven leverage...

Regeneron Pharmaceuticals (REGN) is back in focus after reporting second quarter 2026 results that showed revenue of US$4.29b, alongside a quarterly dividend declaration and a new radiopharmaceuticals collaboration with Telix Pharmaceuticals. See our latest analysis for Regeneron Pharmaceuticals. At a share price of US$762.63, Regeneron Pharmaceuticals has seen a 30 day share price return of 22.08% and a 1 year total shareholder return of 37.21%. This points to building momentum following...

Autohome (NYSE:ATHM) has announced a new share repurchase program of up to US$400 million. The program has been authorized by its Board and is set to run for 12 months, funded entirely from existing cash reserves. See our latest analysis for Autohome. The buyback news lands after a strong short term share price run for Autohome, with a 7 day share price return of 10.0% and a 30 day return of 21.63% helping to lift the 90 day share price return to 24.84%. However, the 1 year total shareholder...

Cullinan Therapeutics reported that it previously received positive feedback from the U.S. FDA following an End-of-Phase 1 meeting for CLN-049, clearing the way for a potentially registrational Phase 2 trial in relapsed/refractory acute myeloid leukemia and additional combination studies in previously untreated patients. The FDA’s alignment on a seamless Phase 2 design and CLN-049’s Fast Track and Orphan Drug designations together underscore the program’s regulatory momentum in a...

The United States market remained flat over the last week but has shown an impressive 18% rise over the past 12 months, with earnings forecasted to grow by 16% annually. In this context, identifying stocks that are potentially undervalued can be crucial for investors seeking opportunities in a dynamic market environment.

In the last week, the United States market has remained flat, yet it has risen by 18% over the past year with anticipated earnings growth of 16% per annum in the coming years. In this environment, identifying stocks that are trading below their intrinsic value can offer potential opportunities for investors seeking to capitalize on undervaluation.

Palomino Laboratories has completed its acquisition of Vega Links, positioning itself as a key player in the next-generation AI interconnect field. This strategic move significantly expands Palomino's addressable market to over $60 billion and accelerates its capabilities in AI infrastructure. With the integration of Vega Links’ expertise in high-speed AI and memory connectivity, Palomino aims to enhance AI interconnect technologies that improve bandwidth, latency, and power efficiency...

The United States market remained flat over the last week but has seen an 18% increase over the past year, with earnings forecasted to grow by 16% annually. In such a landscape, growth companies with high insider ownership can be appealing as they often indicate strong confidence from those closest to the business and potential for robust performance.

The market remained flat over the last week, but over the past 12 months, it has risen 18%, with earnings forecast to grow by 16% annually. Investing in penny stocks—though a somewhat outdated term—still highlights opportunities in smaller or newer companies that can offer great value. By focusing on those with robust financials and a clear growth trajectory, investors can find promising opportunities among these lesser-known stocks.

The United States market has experienced a flat week but has seen an impressive 18% rise over the past year, with earnings projected to grow by 16% annually. In this environment, identifying stocks with strong fundamentals and growth potential can be key to uncovering promising opportunities.

The United States market remained flat over the last week but has seen an impressive 18% rise over the past year, with earnings projected to grow by 16% annually. In this context, dividend stocks can be a valuable addition to portfolios, offering potential income and stability amidst fluctuating market conditions.

XBP Global Holdings, Inc. ( NASDAQ:XBP ) is possibly approaching a major achievement in its business, so we would like...

Scorpio Tankers (STNG) is back on investor radar after reporting record Q2 2026 earnings, with net income of US$387.54 million and a quarterly dividend of US$0.45 per share reaffirmed, alongside balance sheet refinancing moves. See our latest analysis for Scorpio Tankers. Scorpio Tankers' record Q2 has arrived after a strong run in the stock, with the share price at US$77.86 and a year to date share price return of 56.69%, while the 1 year total shareholder return of 70.11% reflects sizeable...

Cintas Corporation previously announced that its Board of Directors approved a higher quarterly cash dividend of US$0.52 per share, payable on September 15, 2026, to shareholders of record as of August 14, 2026. This dividend increase underscores management’s confidence in Cintas’ cash generation and reinforces its pattern of returning capital to shareholders through regular income. We’ll now examine how this higher quarterly dividend shapes Cintas’ investment narrative, particularly its...

In late July 2026, Amneal Pharmaceuticals reported past second-quarter results showing sales of US$796.2 million and net income of US$57.66 million, alongside higher earnings per share versus a year earlier. Alongside these stronger results, the company raised its 2026 net revenue guidance to a range of US$3.10 billion to US$3.20 billion, signaling increased confidence in its operating outlook. Next, we’ll examine how Amneal’s raised full-year revenue guidance reshapes the earlier investment...

Gorman-Rupp (GRC) is back on investors screens after its July 24 earnings release, which showed higher second quarter sales and net income compared with a year earlier. That updated snapshot is now driving fresh attention. See our latest analysis for Gorman-Rupp. At a share price of $81.19, Gorman-Rupp has had a 90-day share price return of 6.62%. Its year-to-date share price return of 68.65% and 1-year total shareholder return of 101.54% indicate strong momentum over both shorter and longer...

Agree Realty Corporation recently reported its second-quarter and first-half 2026 results, showing year-on-year increases in sales, revenue and net income, with second-quarter revenue reaching US$205.10 million and net income US$54.65 million. An interesting takeaway is that while net income grew meaningfully, diluted earnings per share from continuing operations in the quarter edged up only slightly to US$0.44, highlighting the impact of a growing share count on per-share performance. Next,...

Noble (NYSE:NE) is back in focus after a cluster of updates. The company reported a second quarter revenue decline with a swing to net loss, trimmed its 2026 revenue outlook, and reaffirmed its quarterly dividend. See our latest analysis for Noble. The share price reaction around these announcements has been mixed, with a 1-day share price return of 2.32% but a 7-day share price return that is down 1.99%. Over a longer window, the stock shows building momentum, with a 30-day share price...

It's been a good week for Veralto Corporation ( NYSE:VLTO ) shareholders, because the company has just released its...

Oil prices have just taken a sharp step down, with Brent crude at $83.53 a barrel after headlines around renewed US Iran talks and hopes for smoother traffic through the Strait of Hormuz. For transport and shipping stocks, calmer energy markets and fewer supply chain bottlenecks can change the risk and cost picture very quickly. This article looks at three stocks from our Global Transport & Shipping Stocks screener that appear closely exposed to this news. It explores how each could be...

Why International Paper’s latest earnings matter for shareholders International Paper (IP) reported second quarter 2026 earnings with sales of US$6,004 million and a net loss of US$12 million, compared with sales of US$6,142 million and net income of US$75 million a year earlier. For the first half of 2026, the company reported sales of US$11,975 million and net income of US$48 million, compared with sales of US$11,406 million and a net loss of US$30 million in the prior year period. These...

Despite the fact that Vertical Aerospace Ltd.'s (NYSE:EVTL) value has dropped 10% in the last week insiders who sold...

Paymentus Holdings announced that director Adam Malinowski, originally nominated by Accel-KKR, resigned from the Board on July 23, 2026, and was immediately replaced by Accel-KKR managing director Gregory Williams as an independent Class II director whose term runs through the 2029 annual meeting. Williams’ deep background in corporate strategy, finance, and technology investing, combined with Accel-KKR’s ongoing nomination rights, reinforces the private equity firm’s influence over...